MedPath

Endocannabinoid and Psychological Responses to Yoga in Healthy Adults

Not Applicable
Completed
Conditions
Healthy
Interventions
Behavioral: Yoga
Behavioral: Quiet Rest
Registration Number
NCT03710577
Lead Sponsor
University of Wisconsin, Madison
Brief Summary

This study evaluates the acute effect of yoga on plasma levels of endocannabinoids and mood (i.e., mood disturbance, anxiety, pain) compared to one session of quiet rest. Participants completed one session of yoga and one session of quiet rest on two separate days.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
12
Inclusion Criteria
  • greater than or equal to 18 years old and < 45 years old and
  • report being healthy.
Exclusion Criteria
  • Being pregnant or planning to become pregnant,
  • currently smoking,
  • having a history of light headedness or fainting during blood draws or physical activity,
  • having a history of chest pain during physical activity,
  • having a bone, joint, cardiac, or other medical condition that a doctor has said may be worsened by physical activity,
  • taking medications for any chronic diseases such as high blood pressure or diabetes,
  • responding 'Yes' to any of the seven questions on the Par-Q.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
YogaYoga40 minutes of Vinyasa yoga
Quiet RestQuiet Rest40 minutes of quiet rest
Primary Outcome Measures
NameTimeMethod
Change in Plasma Concentration of N-arachidonoylethanolamineThis will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

Plasma concentration of anandamide, one effector of the endocannabinoid system

Change in Plasma Concentration of 2-Arachidonoylglycerol (2-AG)This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

Plasma concentration of 2-AG, one effector of the endocannabinoid system

Secondary Outcome Measures
NameTimeMethod
Change in Total Pain as Measured by the Short-form McGill Pain QuestionnaireThis will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

15-item self-reported pain questionnaire that measures pain "right now." Scores range from 0-45 with higher scores indicating higher pain.

Change in Total Mood Disturbance as Measured by the Profile of Mood StatesThis will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

65-item self-reported mood questionnaire that measures mood "right now." Scores range from 0-200 with higher scores indicating higher mood disturbance.

Change in State Anxiety as Measured by the State-Trait Anxiety InventoryThis will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

20-item self-reported anxiety questionnaire that measures anxiety "right now." Scores range from 20-80 with higher scores indicating higher anxiety.

Trial Locations

Locations (1)

University of Wisconsin-Madison Natatorium

🇺🇸

Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath